Skip to content
Screener

Adaptive Biotechnologies ADPT Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Biodesix, Inc. logo
Biodesix, Inc.BDSX
$1.61M+30.6%
Guardant Health logo
Guardant HealthGH
$28.03M-5.5%
Natera, Inc. logo
Natera, Inc.NTRA
$15.12M+15.8%
Personalis, Inc. logo
Personalis, Inc.PSNL
$6.88M-7.9%
Myriad Genetics logo
Myriad GeneticsMYGN
$7.1M-34.9%
Agilent Technologies logo
Agilent TechnologiesA
$187M-1.1%

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$3.97B+114%
Enterprise value$4.1B+102%
P/S13.4×+4.4×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206546
Line itemMarch 31, 2026December 31, 2025
Accounts payable$9,615$6,467
Accrued liabilities7,4657,700
Accrued compensation and benefits6,21716,992
Current portion of operating lease liabilities8,5138,920
Current portion of deferred revenue49,39745,194
Current portion of revenue interest liability, net5,8044,642
Total current liabilities87,01189,915
Long-term liabilities

Item 1. Financial Statements (Unaudited)

FAQ

What is Adaptive Biotechnologies's operating lease liabilities (current)?
Adaptive Biotechnologies (ADPT) reported operating lease liabilities (current) of $8.51M in Q1 2026.
How has Adaptive Biotechnologies's operating lease liabilities (current) changed year-over-year?
Adaptive Biotechnologies's operating lease liabilities (current) decreased by 18.6% year-over-year, from $10.46M to $8.51M.
What is the long-term trend for Adaptive Biotechnologies's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's operating lease liabilities (current) has grown at a 20.4% compound annual growth rate (CAGR), from $3.53M to $8.92M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Adaptive Biotechnologies's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude